Porgaviximab/Larcaviximab/Cosfroviximab
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NamePorgaviximab/Larcaviximab/Cosfroviximab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[5]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMapp BiopharmaceuticalPublic Health Agency Of Canada'S National Microbiology Laboratory
China Registration ClassN/A
Develop Information
Active CompaniesPublic Health Agency Of Canada'S National Microbiology LaboratoryMapp Biopharmaceutical
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A